PL371131A1 - Zastosowanie alkilo-L-karnityny w leczeniu zaburzeń erekcji - Google Patents

Zastosowanie alkilo-L-karnityny w leczeniu zaburzeń erekcji

Info

Publication number: PL371131A1
Authority: PL; Poland
Prior art keywords: carnitine; propionyl; erectile dysfunction; treatment; combination composition
Prior art date: 2001-12-04

Application number

PL02371131A

Other languages

English (en)

Other versions

PL211211B1 (pl

Inventor

Aleardo Koverech

Andrea Lenzi

Original Assignee

Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-04

Filing date

2002-12-04

Publication date

2005-06-13

2002-12-04 Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

2005-06-13 Publication of PL371131A1 publication Critical patent/PL371131A1/pl

2012-04-30 Publication of PL211211B1 publication Critical patent/PL211211B1/pl

Links

208000010228 Erectile Dysfunction Diseases 0.000 title abstract 2
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title abstract 2
201000001881 impotence Diseases 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 abstract 2
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
WGAOZGUUHIBABN-UHFFFAOYSA-N 1-aminopentan-1-ol Chemical compound CCCCC(N)O WGAOZGUUHIBABN-UHFFFAOYSA-N 0.000 abstract 1
229930008281 A03AD01 - Papaverine Natural products 0.000 abstract 1
229960004046 apomorphine Drugs 0.000 abstract 1
-1 apomorphine prostaglandin Chemical class 0.000 abstract 1
229960001789 papaverine Drugs 0.000 abstract 1
229960003310 sildenafil Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL371131A 2001-12-04 2002-12-04 Zestawienie propionylo-L-karnityny z sildenafilem, kompozycja farmaceutyczna je zawierająca i jego zastosowanie PL211211B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001RM000708A ITRM20010708A1 (it)	2001-12-04	2001-12-04	Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.

Publications (2)

Publication Number	Publication Date
PL371131A1 true PL371131A1 (pl)	2005-06-13
PL211211B1 PL211211B1 (pl)	2012-04-30

Family

ID=11455907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL371131A PL211211B1 (pl)	2001-12-04	2002-12-04	Zestawienie propionylo-L-karnityny z sildenafilem, kompozycja farmaceutyczna je zawierająca i jego zastosowanie

Country Status (16)

Country	Link
US (3)	US20050080018A1 (pl)
EP (1)	EP1450782B9 (pl)
JP (1)	JP4370169B2 (pl)
KR (1)	KR100907938B1 (pl)
AT (1)	ATE309800T1 (pl)
AU (1)	AU2002365847A1 (pl)
CA (1)	CA2465471C (pl)
DE (1)	DE60207442T2 (pl)
DK (1)	DK1450782T3 (pl)
ES (1)	ES2250749T3 (pl)
HU (1)	HU229214B1 (pl)
IT (1)	ITRM20010708A1 (pl)
MX (1)	MXPA04005269A (pl)
PL (1)	PL211211B1 (pl)
SI (1)	SI1450782T1 (pl)
WO (1)	WO2003047563A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRM20040561A1 (it)	2004-11-11	2005-02-11	Sigma Tau Ind Farmaceuti	Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
EP4684831A3 (en)	2009-02-13	2026-03-11	Boehringer Ingelheim International GmbH	Sglt2 inhibitor for improving glycemic control
IT1397867B1 (it) *	2010-02-03	2013-02-04	Brotzu	Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr)	2013-04-05	2019-02-21	Boehringer Ingelheim Int	Empagliflozinin terapötik kullanımları.
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1215378A1 (zh)	2013-04-18	2016-08-26	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
EP3288561B1 (en) *	2015-04-30	2021-03-31	Boehringer Ingelheim International GmbH	Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
AU2017357589B2 (en)	2016-11-10	2023-05-11	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2903579A1 (de) *	1978-02-03	1979-08-09	Sigma Tau Ind Farmaceuti	Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
ES2141463T3 (es) *	1996-03-04	2000-03-16	Sigma Tau Ind Farmaceuti	Medicamento conteniendo un derivado de la carnitina para el tratamiento de la arteriosclerosis obliterans.
IT1290801B1 (it) *	1996-07-05	1998-12-11	Mendes Srl	Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6133281A (en) *	1996-10-24	2000-10-17	Harbor-Ucla Research And Education Institute	NMDA receptor blockers in the therapy of urogenital disease
IT1293539B1 (it) *	1997-07-16	1999-03-01	Sigma Tau Ind Farmaceuti	Composizione nutritiva per soggetti in stato di debilitazione causato da stress
US20020119933A1 (en) *	2000-07-28	2002-08-29	Butler Terri L.	Compositions and methods for improving cardiovascular function
US6241471B1 (en) *	1999-08-26	2001-06-05	General Electric Co.	Turbine bucket tip shroud reinforcement
IT1306722B1 (it) *	1999-10-08	2001-10-02	Sigma Tau Healthscience Spa	Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di

2001
- 2001-12-04 IT IT2001RM000708A patent/ITRM20010708A1/it unknown
2002
- 2002-12-04 DK DK02804338T patent/DK1450782T3/da active
- 2002-12-04 ES ES02804338T patent/ES2250749T3/es not_active Expired - Lifetime
- 2002-12-04 CA CA2465471A patent/CA2465471C/en not_active Expired - Fee Related
- 2002-12-04 JP JP2003548819A patent/JP4370169B2/ja not_active Expired - Fee Related
- 2002-12-04 SI SI200230234T patent/SI1450782T1/sl unknown
- 2002-12-04 WO PCT/IT2002/000758 patent/WO2003047563A1/en not_active Ceased
- 2002-12-04 DE DE60207442T patent/DE60207442T2/de not_active Expired - Lifetime
- 2002-12-04 US US10/497,498 patent/US20050080018A1/en not_active Abandoned
- 2002-12-04 PL PL371131A patent/PL211211B1/pl unknown
- 2002-12-04 MX MXPA04005269A patent/MXPA04005269A/es active IP Right Grant
- 2002-12-04 AT AT02804338T patent/ATE309800T1/de active
- 2002-12-04 KR KR1020047007882A patent/KR100907938B1/ko not_active Expired - Fee Related
- 2002-12-04 EP EP02804338A patent/EP1450782B9/en not_active Expired - Lifetime
- 2002-12-04 HU HU0402062A patent/HU229214B1/hu not_active IP Right Cessation
- 2002-12-04 AU AU2002365847A patent/AU2002365847A1/en not_active Abandoned
2007
- 2007-01-05 US US11/649,796 patent/US20070117762A1/en not_active Abandoned
2011
- 2011-10-25 US US13/280,749 patent/US8343979B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA04005269A (es)	2004-10-11
PL211211B1 (pl)	2012-04-30
US20120041005A1 (en)	2012-02-16
HUP0402062A2 (hu)	2005-02-28
EP1450782A1 (en)	2004-09-01
US20050080018A1 (en)	2005-04-14
KR20050044594A (ko)	2005-05-12
SI1450782T1 (sl)	2006-02-28
HU229214B1 (hu)	2013-09-30
ATE309800T1 (de)	2005-12-15
CA2465471C (en)	2010-10-19
ITRM20010708A1 (it)	2003-06-04
DK1450782T3 (da)	2006-02-20
DE60207442D1 (de)	2005-12-22
ES2250749T3 (es)	2006-04-16
CA2465471A1 (en)	2003-06-12
DE60207442T2 (de)	2006-07-27
AU2002365847A1 (en)	2003-06-17
WO2003047563A1 (en)	2003-06-12
JP4370169B2 (ja)	2009-11-25
JP2005511655A (ja)	2005-04-28
EP1450782B1 (en)	2005-11-16
KR100907938B1 (ko)	2009-07-16
US20070117762A1 (en)	2007-05-24
ITRM20010708A0 (it)	2001-12-04
HUP0402062A3 (en)	2012-09-28
EP1450782B9 (en)	2006-05-17
US8343979B2 (en)	2013-01-01

Publication	Publication Date	Title
TW200505881A (en)	2005-02-16	Tri(cyclo) substituted amide compounds
BE2012C040I2 (pl)	2019-10-16
ZA200104146B (en)	2002-08-21	Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males.
WO2004047830A3 (de)	2004-08-19	Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
UA84271C2 (en)	2008-10-10	Formate salt of o-desmethyl-venlafaxine
NZ577393A (en)	2012-11-30	Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
MXPA02009904A (es)	2004-09-06	Derivados de apomorfina y metodos para su uso.
MXPA03010655A (es)	2007-06-22	Gel oft??lmico de pirenzepina.
IL151646A0 (en)	2003-04-10	Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction
SI1450782T1 (sl)	2006-02-28	Uporaba kombinirane zmesi, ki vsebuje propionil L-karnitin in dodatna zdravila za zdravljenje erektivne disfunkcije
AU2003219981A1 (en)	2003-09-22	Benzimidazole-derivatives for the treatment of sexual dysfunction
HUP0301828A3 (en)	2006-02-28	Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels
ZA200007019B (en)	2002-05-29	Use of prostaglandin agonists to treat erectile dysfunction or impotence.
ZA200400313B (en)	2004-11-01	Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
AP2005003325A0 (en)	2005-06-30	Morpholine derivatives for use as dopamine agonists in the treatment of I.A. sexual dysfunction
IL162154A0 (en)	2005-11-20	Prostagandin composition for the treatment of erectile dysfunction
MXPA04006079A (es)	2004-09-27	Compuestos para el tratamiento de la disfuncion sexual.
GB2400556B (en)	2005-10-19	Therapeutic composition for autoimmune conditions
AU2001237379A1 (en)	2001-11-22	Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
GB0028245D0 (en)	2001-01-03	New therapeutic use
MXPA04000418A (es)	2004-03-18	Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
UA90843C2 (ru)	2010-06-10	Соединения три(цикло)-замещенных амидов
WO2003064394A8 (de)	2003-12-24	5-ring heterozyklen zur verwendung als antiviral mittel
SI1173178T1 (sl)	2006-02-28	Sestavek, ki obsega apomorfin in seldenafil, in njegova uporaba za zdravljenje erektilne disfunkcije
HK1039057A (en)	2002-04-12	Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males